PriceTargets.com logo

Catalyst Pharmaceuticals - CPRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.83
  • Forecasted Upside: 43.94%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 2 Strong Buy Ratings
$22.81 As of 06/18/2025 05:00 PM ET
▼ -0.41 (-1.77%)

This chart shows the closing price for CPRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Catalyst Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CPRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CPRX

Analyst Price Target is $32.83
▲ +43.94% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Catalyst Pharmaceuticals in the last 3 months. The average price target is $32.83, with a high forecast of $36.00 and a low forecast of $30.00. The average price target represents a 43.94% upside from the last price of $22.81.

This chart shows the closing price for CPRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in Catalyst Pharmaceuticals. This rating has held steady since July 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/19/2025
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/18/2025

Latest Recommendations

  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/5/2025Cantor FitzgeraldUpgradeStrong-Buy
3/3/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$28.00 ➝ $32.00
2/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
2/27/2025StephensReiterated RatingOverweight ➝ Overweight$33.00 ➝ $33.00
2/4/2025Robert W. BairdInitiated CoverageOutperform$28.00
2/3/2025Baird R WUpgradeStrong-Buy
1/10/2025HC WainwrightBoost TargetBuy ➝ Buy$30.00 ➝ $35.00
1/9/2025Bank of AmericaReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
11/18/2024StephensInitiated CoverageOverweight$35.00
11/11/2024Truist FinancialBoost TargetBuy ➝ Buy$30.00 ➝ $36.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
8/12/2024HC WainwrightBoost TargetBuy ➝ Buy$26.00 ➝ $30.00
8/9/2024CitigroupBoost TargetBuy ➝ Buy$27.00 ➝ $31.00
8/9/2024Truist FinancialBoost TargetBuy ➝ Buy$25.00 ➝ $30.00
6/6/2024OppenheimerReiterated RatingOutperform ➝ Outperform$29.00 ➝ $29.00
6/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
5/10/2024HC WainwrightBoost TargetBuy ➝ Buy$24.00 ➝ $26.00
3/27/2024OppenheimerReiterated RatingOutperform ➝ Outperform$29.00
3/22/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$34.00
3/14/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$34.00
3/14/2024CitigroupInitiated CoverageBuy$27.00
3/7/2024Bank of AmericaInitiated CoverageBuy$23.00
3/1/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$27.00 ➝ $34.00
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$24.00
12/21/2023OppenheimerInitiated CoverageOutperform$30.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$27.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$24.00
8/11/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$25.00 ➝ $27.00
7/21/2023HC WainwrightReiterated RatingBuy ➝ Buy$24.00
6/21/2023Piper SandlerBoost Target$21.00 ➝ $24.00
6/20/2023Truist FinancialBoost Target$22.00 ➝ $24.00
3/17/2023Cantor FitzgeraldBoost Target$22.00 ➝ $25.00
2/7/2023Piper SandlerBoost Target$20.00 ➝ $21.00
1/19/2023Truist FinancialBoost TargetBuy$18.00 ➝ $22.00
12/21/2022Truist FinancialBoost TargetBuy$17.00 ➝ $18.00
12/21/2022HC WainwrightBoost TargetBuy$18.00 ➝ $24.00
12/20/2022Piper SandlerBoost TargetOverweight$18.00 ➝ $20.00
11/16/2022Piper SandlerBoost Target$18.00
11/10/2022Piper SandlerBoost Target$16.00 ➝ $18.00
8/24/2022Roth CapitalDowngradeBuy ➝ Neutral$10.00 ➝ $15.50
8/11/2022Truist FinancialBoost TargetBuy$12.00 ➝ $17.00
8/11/2022HC WainwrightBoost TargetBuy$12.00 ➝ $18.00
3/18/2022Truist FinancialReiterated RatingBuy$12.00
3/17/2022Piper SandlerBoost Target$8.00 ➝ $8.75
2/7/2022Piper SandlerBoost TargetOverweight ➝ Overweight$7.00 ➝ $8.00
2/7/2022HC WainwrightBoost TargetBuy$9.00 ➝ $12.00
10/1/2021HC WainwrightReiterated RatingBuy$9.00
9/14/2021HC WainwrightReiterated RatingBuy$9.00
8/15/2021Roth CapitalReiterated RatingBuy
8/10/2021Piper SandlerBoost TargetOverweight$5.50 ➝ $6.50
5/12/2021Cantor FitzgeraldBoost Target$8.00 ➝ $11.00
3/18/2021Roth CapitalBoost TargetBuy$6.50 ➝ $7.00
11/10/2020Piper SandlerLower TargetOverweight$6.00 ➝ $5.50
8/11/2020Roth CapitalReiterated RatingBuy
8/11/2020Piper SandlerLower Target$7.00 ➝ $6.00
8/4/2020OppenheimerReiterated RatingBuy$8.00
(Data available from 6/18/2020 forward)

News Sentiment Rating

1.35 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024
  • 21 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2024
  • 13 very positive mentions
  • 13 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2025
  • 12 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2025
  • 28 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2025
  • 32 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2025
  • 38 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2025
  • 37 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2025

Current Sentiment

  • 37 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Catalyst Pharmaceuticals logo
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Read More

Today's Range

Now: $22.81
Low: $22.71
High: $23.27

50 Day Range

MA: $23.91
Low: $21.45
High: $26.31

52 Week Range

Now: $22.81
Low: $14.75
High: $26.58

Volume

1,465,950 shs

Average Volume

1,135,181 shs

Market Capitalization

$2.78 billion

P/E Ratio

14.53

Dividend Yield

N/A

Beta

0.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Catalyst Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Catalyst Pharmaceuticals in the last twelve months: Baird R W, Bank of America Corporation, Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Robert W. Baird, Stephens, Truist Financial Corporation, and Wall Street Zen.
View the latest analyst ratings for CPRX.

What is the current price target for Catalyst Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Catalyst Pharmaceuticals in the last year. Their average twelve-month price target is $32.83, suggesting a possible upside of 43.9%. Truist Financial Corporation has the highest price target set, predicting CPRX will reach $36.00 in the next twelve months. Bank of America Corporation has the lowest price target set, forecasting a price of $30.00 for Catalyst Pharmaceuticals in the next year.
View the latest price targets for CPRX.

What is the current consensus analyst rating for Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals currently has 6 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CPRX will outperform the market and that investors should add to their positions of Catalyst Pharmaceuticals.
View the latest ratings for CPRX.

What other companies compete with Catalyst Pharmaceuticals?

Other companies that are similar to Catalyst Pharmaceuticals include Ascendis Pharma A/S, Viatris, Qiagen, Moderna and Blueprint Medicines. Learn More about companies similar to Catalyst Pharmaceuticals.

How do I contact Catalyst Pharmaceuticals' investor relations team?

Catalyst Pharmaceuticals' physical mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company's listed phone number is (305) 420-3200 and its investor relations email address is [email protected]. The official website for Catalyst Pharmaceuticals is www.catalystpharma.com. Learn More about contacing Catalyst Pharmaceuticals investor relations.